TENS for Limb Function in Stroke: Design and Rationale for a Randomized Trial
Launched by CHENGNING SONG · May 21, 2025
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at whether different speeds of electrical nerve stimulation, known as TENS, can help improve arm movement in people recovering from a stroke. Participants will receive TENS treatment on their weaker arm three times a week for eight weeks. The goal is to find out which TENS setting works best to support recovery after a stroke.
To be eligible for this study, participants should be between 18 and 85 years old and must have had a stroke within the past 10 days to 2 months. They need to have some movement in their non-weak arm and at least a little movement in their weak arm's shoulder. Participants must also be able to provide consent to join the study. This trial is not yet recruiting, so it’s a good time to learn more if you think you or someone you know might be interested!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18 to 85 years
- • 2. Clinical diagnosis of stroke (ischemic or hemorrhagic) within the past 10 days to 2 months
- • 3. Presence of voluntary movement in the non-paretic arm and at least minimal antigravity movement in the paretic shoulder
- • 4. At least 5 degrees of active wrist extension on the paretic side
- • 5. Able to provide informed consent
- Exclusion Criteria:
- • 1. Uncontrolled medical, cardiovascular, or orthopedic conditions
- • 2. Contraindications to TENS (e.g., implanted cardiac pacemaker, skin allergies)
- • 3. Receptive aphasia preventing informed consent or cooperation
- • 4. Significant peripheral neuropathy affecting upper limbs
- • 5. Current participation in another clinical trial or drug study
- • 6. Severe contractures in the shoulder, elbow, wrist, or fingers
About Chengning Song
Chengning Song is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing novel therapeutic solutions, Chengning Song oversees the design, implementation, and management of clinical studies aimed at evaluating the safety and efficacy of new treatments. By fostering collaboration with research institutions and healthcare professionals, the organization strives to enhance patient outcomes and contribute to the evolving landscape of healthcare. Through rigorous adherence to regulatory standards and ethical practices, Chengning Song is dedicated to delivering high-quality clinical evidence that supports the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shenzhen, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported